CD8A and cancer: To assess whether Tpex2 is resistant to ICI response across cancer types beyond HNSCC, we analyzed single-cell transcriptome data from ICI-treated samples of various cancers and compared tumor-reactive CD8+ T cell subsets using a label transfer approach (STAR Methods).